Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
A personalized mRNA cancer vaccine developed by Moderna and Merck reduced the risk of death or recurrence by 42% in a Phase 3 trial involving 1,137 patients with stage IIB–IV melanoma. The results are...